Updated Data Matrix Available

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals

Global Insulin Pump Patches Market $1.9 Billion by 2029

The global market for insulin pump patches estimated to reach $1.9 billion by 2029, expanding at a double-digit CAGR of 11.4% over the forecast period, driven by increasing prevalence and incidence of diabetes as well as diabetes-related disorders, and growing demand for novel and easier-to-use miniature devices worldwide.

  • Patch pumps are novel insulin delivery systems that have emerged on the market, offering flexible insulin delivery options. These systems offer several advantages over conventional insulin pump delivery systems and are gaining popularity. Patch pumps are free of tubing, small, and lightweight.
Global Insulin Pump Patches Market

According to the International Diabetes Federation (IDF), approximately 537 million adults were living with diabetes in 2022 and this number expected to reach 643 million by 2030. The global diabetic population is expected to reach 783,700 by 2045, which includes a significant number of older people. Although most patients use insulin pens or syringes, a substantial proportion of people with type 1 diabetes and a sizable minority of patients with type 2 diabetes have chosen to use an insulin pump.

  • Newly developed patch pumps are starting to occupy a noticeable fraction of the insulin delivery market. New entrants, using novel technologies, promise accurate, flexible insulin delivery at lower costs.
    • Insulin patch pumps vary in complexity and may offer appropriate functionality in both type 1 and type 2 diabetes (T1D and T2D). Insulin pumps are used by a steadily increasing number of patients with diabetes.
      • They can deliver basal insulin, bolus insulin, or both. Avoiding certain disadvantages of conventional pumps (i.e., the insulin infusion set) might make pump therapy even more attractive.
        • Patch pumps are usually attached by means of an adhesive layer to the skin and have several additional advantages (smaller, more discrete, easier to use, and cheaper than conventional insulin pumps).

The global insulin patch pumps market research report provides market size ($million 2021 to 2031), market share analysis, growth trends and forecast (CAGR%, 2024 to 2031).

The global market for insulin pumping patches segmented by product (disposable insulin patch pumps, reusable insulin patch pumps), delivery mode (basal, bolus, basal & bolus), distribution channel (hospitals, retail pharmacies, private clinics, online pharmacies, others), and geography.

  • Based on the products, the reusable insulin patch pumps segment dominated the global market and expected to continue its dominance during the forecast period, mainly due to increasing product launches, and rapid adoption by majority of the diabetic population in the developing countries.
    • The conventional continuous subcutaneous insulin infusion (CSII) therapy pumps tend to be bulky, expensive, and tether the patient by tubing. Insulin infusion sets (IIS) can be prone to clogging, kinking of the tubing, or obstruction of insulin delivery with air bubbles.
    • In contrast, patch pumps are generally smaller and attach directly to the skin without tubing. Surveys indicate that most patients with T1D prefer insulin pumps without visible IIS; making patch pumps an attractive insulin delivery option.
      • The disposable insulin patch pumps are simplified (mechanical only) or full featured (mechanical pump with electronic controller) devices. All are disposable or semi-disposable, and do not require use of a catheter.
        • These pumps utilize electro-chemiosmotic rather than mechanical pumping, allowing for accurate delivery of very small amounts of insulin including concentrated insulins.
          • Most of the patch pumps have some disposable components and some are completely disposable. Patch pumps are used by about 5% of people who use insulin pumps or about 25,000 people worldwide, most using the Omnipod by Insulet.

The simplified devices include V-Go, PAQ, and One Touch Via, and the more complex devices include Omnipod, Cellnovo, JewelPump, Solo, SFC Fluidics pump, Libertas, Medtronic pump, and EOPatch. These simplified devices are generally geared toward T2D.

  • Of these, V-Go (MannKind Corporation) is the only one available in the U.S., which must be replaced daily. The PAQ, a 3-day device with a small reusable electronic portion by Cequr Corporation is available in Europe.
  • Omnipod (Insulet Corporation) is only one full-featured device available in the U.S. It offers a range of functionalities (e.g., variable basal rates, controlled bolus amounts, advanced bolus options). The Omnipod DASH by Insulet is another full-featured device currently used as the Omnipod Insulin Management System in Europe, Canada, and the U.S.
    • In addition to improved glycemic control, patients reported improved quality of life (QOL) with use of the Omnipod system compared to their previous treatment modality.

The global market for insulin pump patches research report is further segmented by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of the World.

  • In terms of geography, the North America region, followed by Europe accounted for the largest revenue share of the total insulin pumping patches market, attributed to premium-priced products, increasing expenditure on diabetes care, favorable reimbursement policies, early launch and rapid acceptance of newer devices, and well-defined regulatory networks.
    • Approximately 30 million people in the U.S. have diabetes mellitus (DM), and nearly 9 million of these would be estimated to be on insulin therapy. Employment of CSII or insulin pump therapy for insulin delivery has increased over the years, the vast majority occurring in the type 1 DM population.
      • Insulin patch pumps are an emerging technology and represent an exciting addition to the insulin delivery options currently available to patients.
  • However, the Asia Pacific region anticipated to witness the fastest growth rate in the coming years, owing to rapidly growing diabetic population requiring insulin therapy, increasing awareness on self-monitoring of blood glucose, lower cost of products, improving diabetes care infrastructure, and availability of innovative diabetes management solutions in the emerging countries.  
    • Diabetes is prevalent and has high morbidity and mortality rates in the Asia Pacific (APAC) region. According to the IDF, one in eleven adults in Southeast Asia (SEA) and one in eight adults in the Western Pacific (WP) region had diabetes in 2021, with projected 68% and 26% increases, respectively, by 2045.

In addition, the global market insulin patch pumps market report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries. The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.

Major competitors operating in the global market for insulin pumping patches and profiled in this report include CeQur Corporation, Debiotech S.A., Insulet Corporation, MannKind Corporation, Medtronic plc (EOFlow Co., Ltd.), Medtrum Technologies, Inc., Platinum Equity Advisors, LLC (LifeScan IP Holdings, LLC), Roche Holding AG, Tandem Diabetes Care, Inc., and Terumo Corporation.

  • Product
    • Disposable Insulin Patch Pumps
    • Reusable Insulin Patch Pumps
  • Delivery Mode
    • Basal Delivery
    • Bolus Delivery
    • Basal and Bolus
  • Distribution Channel
    • Hospitals
    • Retail Pharmacies
    • Private Clinics
    • Online Pharmacies
    • Others
  • Geography
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Rest of the World
  • Company Profiles
    • CeQur Corporation
    • Debiotech S.A.
    • Insulet Corporation
    • MannKind Corporation
    • Medtronic plc (EOFlow Co., Ltd.)
    • Medtrum Technologies, Inc.
    • Platinum Equity Advisors, LLC (LifeScan IP Holdings, LLC)
    • Roche Holding AG
    • Tandem Diabetes Care, Inc.
    • Terumo Corporation

To request Table of Contents and Sample Pages of this report:

Related publications:

    Request ToC/Sample information for this market analysis

    Full Name*

    Company Email*

    Phone Number* [Please add country code]



    Secure Online Payment

    iHealthcareAnalyst, Inc.

    Contact Address

    US Office: 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States
    Phone: +1 (314) 315-4764
    India Office: 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India
    Phone: +91 (20) 25898524
    Email: sales@ihealthcareanalyst.com